Badrilla
Private Company
Funding information not available
Overview
Badrilla is a specialized reagent and tool provider focused on cardiovascular research and protein post-translational modifications, particularly S-palmitoylation. The company leverages proprietary technology for quantitative western blotting to deliver accurate biomarker measurements, positioning itself as a critical partner for research teams. While not a therapeutic developer, its products enable fundamental discoveries in cardiac function and disease mechanisms, operating as a private, revenue-generating entity within the research tools and services sector.
Technology Platform
Proprietary technology for quantitative western blotting enabling accurate and precise biomarker measurement. Expertise in generating and validating antibodies for cardiac proteins and phospho-proteins, and in developing assay kits for protein S-palmitoylation analysis.
Opportunities
Risk Factors
Competitive Landscape
Operates in a crowded research reagents market dominated by global giants like Abcam and Thermo Fisher. Competes by offering deep specialization, high-validation standards, and proprietary quantitative technology in specific niches like cardiac phospho-proteins and S-palmitoylation kits, rather than breadth of catalog.